The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)

<p><span style="color: rgb(51, 51, 51);">The Accelerating Medicines Partnership (AMP), is a pre-competitive collaboration among government, academia, and industry to improve the ongoing efforts to develop new therapies for complex, heterogeneous diseases (</span><a href="http://www.nih.gov/science/amp/" target="_blank" style="color: rgb(31, 107, 178);">http://www.nih.gov/science/amp/</a><span style="color: rgb(51, 51, 51);">). The overarching goal of AMP CMD is to use human genetics as a powerful approach to obtain human-data derived disease understanding and biomarker/therapeutic opportunities. This is being accomplished through systematic aggregation of existing genotype-phenotype data for CMD, related traits, and its complications as well as the generation of a large amount of new omic data. The goal of the NIDDK-funded component of the consortium is to aid in advancing the understanding of the mechanisms responsible for T2D development through the integration of large-scale genetic data that will contribute to further deconstruction of the pathophysiology of T2D, and potentially of its major complications, including macrovascular and microvascular disease.&nbsp;The purpose of this is to request is for renewal of the AMP CMD UM1 program for another 5 years for the portal to aggregate and collate data on T2D/CMD genes and their functional variants so that it can be queried by the scientific community.</span></p>